Phosphagenics Signs a Multinational License for TPM® in Personal Care Products
Phosphagenics Signs a Multinational License for TPM® in Personal Care Products 4 December 2017, Melbourne: Australian drug delivery company, Phosphagenics Limited (ASX: POH; OTCQX: PPGNY), is pleased to announce the signing of a non-exclusive license agreement with Rodan…
Major $640 million investment in Australia’s world-leading medical research
The Turnbull Government will invest $640 million to support Australia’s world-leading health and medical researchers as they continue their work in the laboratory, clinic and the community to find the next major medical breakthrough. Cancer research continues to…
$33 million for CRC Projects to tackle diverse industry problems
http://minister.industry.gov.au/ministers/laundy/media-releases/33-million-crc-projects-tackle-diverse-industry-problems?mc_cid=da234fdd4a&mc_eid=1eb046c0f3 Better barramundi breeding, disease resistant bananas, a portable brain scanner for early stroke detection and a process to turn waste plastics into spectacle frames are amongst 15 highly diverse industry-led projects to receive a $33 million investment…
$2.5M GRANT AWARDED TO ADVANCE WOUNDVUE™ DEVELOPMENT
• Joint collaboration with University of Melbourne and Planet Innovation Adelaide, Australia, 7 December 2017: Australian medical technology company, LBT Innovations Limited (ASX:LBT) is pleased to announce it has been awarded a $2.513 million grant to advance the…
IDT Australia Executes API Development Agreement
• API Development Agreement executed with The State Government of Victoria • Total consideration over AUD 2,000,000 over the twelve month term of the project Australian pharmaceutical manufacturing and drug development company IDT Australia Limited (ASX:IDT) announces it…
Prima BioMed has just announced new clinical data from its TACTI-mel Phase I trial in Australia – which is investigating Prima’s lead drug, IMP321, in combination with KEYTRUDA in metastatic melanoma
Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD) (“Prima”) is pleased to announce the presentation of new data from its TACTI-mel Phase I clinical trial in Australia investigating the use of eftilagimod alpha (LAG-3Ig or IMP321), the Company’s lead…
AdAlta appoints Dr Dallas Hartman as Chief Operating Officer
AdAlta Limited (ASX: 1AD), the biotechnology company advancing its lead i-body candidate towards clinical development, is pleased to announce the appointment of experienced executive, Dr Dallas Hartman to the role of Chief Operating Officer. Dr Hartman will bring…
Patrys and Garvan Institute of Medical Research Awarded Grant
Patrys Limited (ASX: PAB), a clinical stage biotechnology company and Sydney’s Garvan Institute of Medical Research (Garvan) have recently finalized the terms of a Federal Government Innovation Connections grant to support research within the PATDX1 program. The Garvan…
New US patent for Patrys PAT-LM1
Patrys (ASX:PAB), a clinical stage biotechnology company, has been granted a US patent for its anti-cancer pre-clinical candidate PAT-LM1. The US Patent Office has issued correspondence confirming the grant of a key patent in the PAT-LM1 family, patent…
Universal Biosensors receives $7.5M under the R&D Tax Incentive
Universal Biosensors (ASX:UBI) today announced it has received $7.5M in cash under the R&D Tax Incentive for the 2016 financial year. The R&D Tax Incentive is an Australian Government program developed to assist eligible businesses recover some of…
Medical Device Industry Sign Historic Agreement to Reduce Health Fund Premiums
The Medical Technology Association of Australia (MTAA) has signed a four-year Agreement with the Federal Government which will deliver certainty and stability to the industry and will help lower Private Health Insurance (PHI) premiums for Australians. The Agreement,…
GKC names John Schellhorn new President and CEO
GKC announced today that it has appointed John Schellhorn as its new President and CEO. Schellhorn will also be joining the company’s Board of Directors. Schellhorn joins GKC with a proven track record to spearhead the company’s accelerated…
